07:52 AM EST, 11/11/2024 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Monday it has granted ALK-Abello exclusive rights to commercialize neffy nasal spray, its emergency treatment for Type I allergic reactions, in Europe, Canada, and other territories outside the US.

Under the licensing agreement, ARS Pharmaceuticals ( SPRY ) said it will receive $145 million upfront and up to $320 million in milestone payments, along with royalties.

ARS will manufacture and supply neffy to ALK-Abello and retain US rights while there are no changes to partnerships for neffy in Japan, China, Australia and New Zealand, ARS Pharmaceuticals ( SPRY ) added.